PF-Atlas › Clinical Trials › NCT02057458

Blood Flow and Vascular Function in Cystic Fibrosis

Sildenafil · Phase 2

Registry ID
NCT02057458
Phase
Phase 2
Status
Completed
Drug / intervention
Sildenafil (Acute-1 hour)
Sponsor
Augusta University
Start
2014-04
Enrollment
19
Locations
1

About this trial

Cystic fibrosis (CF) has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators laboratory recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how 1) blood flow and 2) artery function contribute to exercise capacity in CF.

View NCT02057458 on ClinicalTrials.gov →

Explore related

All Sildenafil trialsAll IPF trials

Related trials

sildenafil — NCT00359736Sildenafil — NCT00352482sildenafil — NCT00659529Sildenafil — NCT01194232Sildenafil — NCT00981747sildenafil — NCT02626182
Medical disclaimer. This page summarizes public trial data for NCT02057458 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.